Drug intelligence / Profile preview

Birmex

Development stage: Phase 3
Lead developer: BIRMEX
Modality: Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Oral, Intravenous, Intramuscular

Overview

Birmex is a Mexican state-owned manufacturer of various biological pharmaceutical products, including anti-scorpion serums, polio vaccines, and polyspecific antivenoms for snakebites. Its antivenoms, such as Faboterápico Polivalente Antiviperino, are composed of F(ab')2 antibody fragments designed to neutralize toxins from a range of snake species, including Crotalus and Bothrops. The company also produces Oral Polio Vaccine (OPV) to induce immunity against poliovirus and anti-scorpion serums to treat scorpion sting intoxication.

Brand names: BirmexFaboterápico Polivalente Antiviperino

Targets

Snake venom toxins from Crotalus basiliscus

Beyond the preview

Go deeper on Birmex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Birmex.

Explore the full profile